Longeveron Inc. (NASDAQ:LGVN) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET

Company Participants

Elsie Yau - Stern Investor Relations, IR

Geoff Green - CEO

Chris Min - Chief Medical Officer

James Clavijo - CFO

Joshua Hare - Chief Science Officer

Conference Call Participants

Michael Okunewitch - Maxim Group

Constantine Davides - EF Hutton

Operator

Hello everyone and welcome to the Longeveron Inc. 2022 First Quarter Earnings Call. My name is Juan and I will be coordinating your call today. All participants have been placed on mute to prevent any background noise. There will be a question and answer session at the end of the presentation. [Operator Instructions].

I will now like to turn the call over to Elsie Yau from Stern Investor Relations. Please Elsie, you may proceed.

Elsie Yau

Thank you, operator. Good morning, everyone and welcome to Longeveron's first quarter 2022 call. Today we will provide a business update and discuss financial results for the first quarter of 2022. Earlier this morning, we issued a press release with these results, which can be found under the investor section of our website at www.longeveron.com.

I'm joining the call today by the following members of Longeveron's Management team, Geoff Green, Chief Executive Officer; Dr. Joshua M. Hare, Co-Founder, Chief Science Officer and Chairman; Dr. Chris Min, Chief Medical Officer, and James Clavijo, Chief Financial Officer.

Mr. Green will begin with a brief corporate overview, followed by Dr. Min who will provide updates to our clinical pipeline. And finally Mr. Clavijo will review our 2022 first quarter financial results. We will then open the call for Q&A.

As a reminder, during this call, we'll be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussion in our filings with the SEC, including our Annual Report and Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now, I'd like to turn the call over to Geoff Green, Chief Executive Officer of Longeveron. Geoff?

Geoff Green

Thank you, Elsie. Good morning, everyone. It's my pleasure to welcome you to Longeveron's first quarter 2022 business update and financial results call. Longeveron is a leading clinical stage biotechnology company developing living cell therapies for chronic aging related diseases and other specific life threatening conditions. We are driven by our mission to develop safe and effective cell based therapies for some of the most challenging disorders associated with the aging process and other medical disorders.